Telix Pharmaceuticals
- Market cap
- 3.77B
- P/E (TTM)i
- 114.64
- P/Bi
- 9.07
- EPSi
- -0.02
- Div yieldi
- 0.00%
- 52W posi
- 71%
Anonymous reader poll. Unscientific, not investment advice.
About Telix Pharmaceuticals
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
- Founded
- 2017
- CEO
- Dr. Christian Behrenbruch, M.B.A.,PhD
- Employees
- 1,184
- Headquarters
- Melbourne, Victoria (VIC), Australia
- Fiscal year end
- 12-31
- Website
- telixpharma.com
Company profile
- Exchange
- US
- Symbol
- TLX
- Market-cap rank
- #2345
- Listing date
- 2024-11-14
- Market cap
- 3.77B
- Float cap
- 3.02B
- Shares out
- 338.78M
- Float shares
- 271.65M
Sectors & themes
Quote time 2026-10-08 07:11:57 · For reference only, not investment advice and not tailored to your situation.